

Supplemental Information

Mosaic Activating Mutations in *FGFR1* Cause

Encephalocraniocutaneous Lipomatosis

James T. Bennett, Tiong Yang Tan, Diana Alcantara, Martine Tétrault, Andrew E. Timms, Dana Jensen, Sarah Collins, Malgorzata J.M. Nowaczyk, Marjorie J. Lindhurst, Katherine M. Christensen, Stephen R. Braddock, Heather Brandling-Bennett, Raoul C.M. Hennekam, Brian Chung, Anna Lehman, John Su, SuYuen Ng, David J. Amor, Jacek Majewski, Les G. Biesecker, Kym M. Boycott, William B. Dobyns, Mark O'Driscoll, Ute Moog, Laura M. McDonell, University of Washington Center for Mendelian Genomics, and Care4Rare Canada Consortium

1 **SUPPLEMENTAL DATA**

2 **TABLE S1.** Capture methods and coverage summary of exome data

	LR12-068		LR13-278			LR13-175		IN_0039		NIH_183	
	Tumor*	Scalp nevus	Unaffected skin	Scalp nevus	Eyelid dermoid	Scalp nevus	Lipoma	Scalp nevus	Unaffected skin	Scalp nevus	Blood*
Capture Method	SeqCap EZ Exome Library v2.0 kit							SureSelect All Exon V5		SeqCap EX Exome+UTR	
Mean Coverage	122X	160X	161X	160X	150X	169X	172X	106X	105X	65X	64X
% Covered > 20X	95.9	97.7	97.3	97.1	96.6	97.8	97.9	94.7	94.7	83.1	84.4
c.1638C>A (p.Asn546Lys)	0% (47)	0% (98)	35% (74)	42% (99)	54% (92)	0% (93)	0% (105)	33% (76)	23% (61)	0% (24)	0% (39)
c.1966A>G (p.Lys656Glu)	32% (127)	47% (182)	0% (219)	0% (172)	0% (181)	0% (202)	0% (205)	0% (70)	0% (90)	45% (29)	0% (40)

3 All DNA isolated from cultured fibroblasts cultured from biopsied tissue except those with asterisk
 4 (*), in which DNA was directly isolated from tissue without culture.

5
6

7 **TABLE S2:** Exome sequencing and variant filtering pipelines

<i>Sample</i>	LR12-068, LR13-278, LR13-175	IN_0039	NIH_183
<i>Sequencing platform</i>	HiSeq 2000 (Illumina)	HiSeq 2000 (Illumina)	HiSeq 2500 (Illumina)
<i>Sequence alignment</i>	Burrows-Wheeler Aligner	Burrows-Wheeler Aligner	Novoalign
<i>Variant calling & annotation</i>	Unified Genotyper, SeattleSeq Annotation Server	GATK, SAMtools, BCFtools, custom script	Shimmer, Mutect, Somatic Sniper
<i>Filtering</i>	missense,nonsense, & splice variants with < 1% in EVS, ExAC, & dbSNP	missense,nonsense, & splice variants with < 1% in EVS, ExAC, & dbSNP. Not seen in > 5 in-house exomes	missense, nonsense and splice variants with < 2% ClinSeq™ frequency*

8 *ClinSeq™ frequency is defined as the number of individuals with alternative allele
 9 frequency ≥1%, divided by the number of individuals with at least ten reads at that
 10 position. This is a population frequency based filter that is not limited to constitutional
 11 variants (as is the case with EVS, EXAC, and dbSNP), and is based on the NIH in house
 12 ClinSeq dataset (www.genome.gov/25521305)

13
14

15 **TABLE S3:** Primers used for subcloning 1408 basepair fragment containing c.1681G>A
 16 (p.Val561Met) and c.1966A>G (p.Lys656Glu)

17

Name	Sequence
FGFR1_ex14_F	CTTTGAGGTGAAGCCAAACC
FGFR1_ex15_R	ACCCCACTCCTTGCTTCTC

18

1 **TABLE S4:** Sequences for *FGFR1* smMIPs

Name	Sequence
FGFR1_01	GAGCTCTGGCTCTGGCACGGGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNGGGTGTGGGAAAGCTGGGGG
FGFR1_02	CACGCCCTCCCAGACTCCACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTTCCCGACACCCGGAGCTCTACGT
FGFR1_03	GGGCCCTCCTCCCTGCTCAGGGAGGTGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNATGAGAGAAGACGGAA
FGFR1_04	CCCACTGCGTGACGCACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNGTACATGATGATCGGGACTGTGGC
FGFR1_05	CGTCTCTGGAGATGGATACTCTAGTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNCTGGTTGGAGGTCAA
FGFR1_06	GCAAAATGGGCGGAGAGCCACAGGGTGTACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTGGTGCACTTACTGGG
FGFR1_07	TGAGCCAGGCCTGGGGCACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTGGGAGATCTTACTCTGGGCGG
FGFR1_08	CGCATGGACAAGCCAGTAACTGCACCAACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNAACACCTGTGGCTCT
FGFR1_09	TGGCCCAAGCAGGGCCATGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTCTCTATCCACACCTCCCTGGCA
FGFR1_10	CCTCTGTACCAGGACATTCTGGCTGCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNACTCCTTGCTTCTCA
FGFR1_11	CGCACGGGACATTACCACATCGACTACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNCAGAGCCTTCCAGCTC
FGFR1_12	GGGTTGTGGCTGGGGTGTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNAAGACTAGGGGGGCTGTGCCAC
FGFR1_13	AGCAGCTCTCTCAAGGACTGGTGTCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTTCTCTGTGCTCG
FGFR1_14	CCACCCCAAGCAGCACACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNGGGGCTCCGGGCTGCAGGACTCC
FGFR1_15	GCTAGGGAAGGGGTTAAGAGAGGCTGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNGGGAAGCATAAGAATA
FGFR1_16	CGCAGGATGGTGGTGCCGGCAGACTGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNCAAGTAAATGAGTCTCA
FGFR1_17	CCCATTCAAGCAAACAGCAGGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTGGGAGAGGGCTGCTTTGGG
FGFR1_18	CGTGTGACCAAAGTGGCTGTGAAGATGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNAACTTACCAGCCCAA
FGFR1_19	CGAACCAGAAGAACCCAGAGTTCATGGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNAATGCCTTCAAAAAGT
FGFR1_20	GCAAGGAGGGGGACGGGGTACTCTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTCATACTCAGAGACC
FGFR1_21	TGCACACTCAGCACCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNATCTCTGCATGGTGGGGTCCGGTATC
FGFR1_22	GGTACCAAGAAGAGTGACTTCCACAGCCACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNACTGACTCAGCCCTG
FGFR1_23_SNP _a	AGGCC G GCAGTGATGACCTCGCCCTGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNATGGTTCTTCTCCCT
FGFR1_23_SNP _b	AGGCC A GCAGTGATGACCTCGCCCTGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNATGGTTCTTCTCCCT
FGFR1_24_SNP _a	CGTGCC C GTGGCGAGGGCAGGACATCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNCTAGGGAAGCTCTTCTC
FGFR1_24_SNP _b	CGTGCC T GTGGCGAGGGCAGGACATCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNCTAGGGAAGCTCTTCTC
FGFR1_25	GGGGAGACACAGAGGCAGGAGAGCTGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNGTCTTGGCGGGTAAAC
FGFR1_26	CGGAAGCAAAATGGACAAGCACAGGACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNAGTGATGGGAGAGTC
FGFR1_27	CGTCACTGGGGCTTTGGGGTCACTTCACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNACACACTCCATCTCA
FGFR1_28	AGTAACAGAGGTCACAAAGTGGAGGTGAGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTGGGAAGGAGACCAT
FGFR1_29	CGGGGGCTCAAGTCTCTGTGGGACGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNGCACATCCAGTGCTAAAG
FGFR1_30	CGGTGAGGGGACCGCTCTGTGGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNAACTTGTCTCCATTACCTC
FGFR1_31	GGGTGGGCTCACTGCGCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTTACACATGAACCTCCAGTTGCTACC
FGFR1_32	AAGAGCCAGGCTTGGAGAACACAGCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTGGACTCTGTGGTGCCT
FGFR1_33	GGCAACTACACTGATTGTGGAGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNAGGTGCCACGGGGTGC
FGFR1_34	AGGGGAGGCCGAGTTAGGAAGTCTGATTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNCAAATGCCCTTCCAGT
FGFR1_35	GGGACCCCAAACCCACACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNAGTCTCTTCCACCTGCCT
FGFR1_36	GGGAAGAAGAAGGGGCACTGAGGTTCTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNCAGACCAAAGGGCAG
FGFR1_37	GGACACCTCCCATGGGGATCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTTCTCTCTGAAGAGGAGTCA
FGFR1_38_SNP _a	GGGCAC G GAGTCTGCACCTCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTGGCAGAGAGGGCTGGAGGGG
FGFR1_38_SNP _b	GGGCAC A GAGTCTGCACCTCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTGGCAGAGAGGGCTGGAGGGG
FGFR1_39	TGCTCTGCACATGTCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTGGTGTACTGCCGAGGGGCTGCTG
FGFR1_40	TCAACTGGCTGCGGACGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTCTCTGCCCTTGGCTCCCTTC
FGFR1_41	CGTAATAAAAAAACCCTTCGAGAGGGCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTTGGGGCTCTCTCC
FGFR1_42	GGGCAGCTGGACTCTGGGCTTGGGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTACCAACCTTAACT
FGFR1_43	GGATGTGGAGCTGGAAGTGCCTCTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTCCCTACCTAGACCT
FGFR1_44	CCCTCTGATGAGTGGGAAACTGAGATGTGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNTACTCTACCAGACAC

2 Sequences of all 47 smMIPs used in this study are listed. The string of five N's
 3 represents the degenerate molecular tag. Three smMIPs overlapped a common SNP, so
 4 smMIPs complimentary to both alleles (in red) were used, and labeled "a" and "b"

1 **TABLE S5:** Coverage depth at the two *FGFR1* mutation sites for each sample
 2 sequenced by smMIPs
 3

Cohort	Individual	Tissue	c.1638C>A (p.Asn546Lys)	c.1966A>G (p.Lys656Glu)
Exome sequencing	LR13-278	Unaffected Skin	50/160 (31%)	0/22
		Scalp Nevus	52/108 (48%)	0/12
		Eyelid Dermoid	42/76 (55%)	low coverage
		Blood	0/153	0/29
		Saliva	0/27	0/28
	IN_0039	Scalp Nevus	30/83 (36%)	low coverage
		Saliva	0/114	low coverage
		Buccal	0/40	low coverage
		Blood	0/51	low coverage
	Tissue biopsy available	LR14-261	Scalp Nevus	110/199 (55%)
Saliva			0/36	low coverage
LR04-090		Unaffected skin	0/119	0/22
		Saliva	0/228	0/36
		Blood	0/119	0/23
LR09-120		Scalp Nevus	0/35	0/19
		Saliva	0/124	0/24
IN_0025		Lipoma	0/117	0/22
		Blood	0/211	0/26
		Saliva	0/94	0/25
Blood/Saliva Only	LR04-093	Blood	0/152	0/39
	LR09-252	Saliva	0/105	0/28
	LR14-210	Blood	0/227	0/49

4 Low coverage was defined as less than 10 independent reads
 5
 6